Bank of America vs Bristol-Myers Squibb: Founders, CEOs and History
Bank of America was founded in 1904 by Amadeo Peter Giannini and is led by Brian Moynihan. Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner.
Company facts
Bank of America
- Founded
- 1904
- Headquarters
- Charlotte, North Carolina
- Current CEO
- Brian Moynihan
- Employees
- 213,000
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Founders
Bank of America
Amadeo Peter Giannini
Bank of America was founded by A. P. Giannini, the San Jose-born son of Italian immigrants. In 1904 he opened the Bank of Italy in a converted saloon in San Francisco's North Beach neighborhood. His aim was unusual for the time: to lend to working people.
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
CEOs and their tenures
Bank of America
- Amadeo Peter Giannini1904–1945
Founder and Chairman
Giannini was born in San Jose, California, in 1870 to Italian immigrant parents and sold fruit and vegetables from a horse-drawn wagon before opening the Bank of Italy in San Francisco at the age of 34.
Source - Hugh L. McColl Jr.1998–2001
Chairman and Chief Executive Officer
McColl joined the company in 1959 as a management trainee and built NationsBank through interstate acquisitions before its 1998 combination with San Francisco based BankAmerica, which took the Bank of America name and created the first coast-to-coast U.S.
Source - Ken Lewis2001–2009
Chairman and Chief Executive Officer
Lewis joined the company in 1969 as a credit analyst, ran corporate strategy from 1999, and became chairman and chief executive officer on April 25, 2001 when Hugh McColl retired.
Source - Brian Moynihan2010–present
Chair of the Board and Chief Executive Officer
Moynihan became chief executive officer on January 1, 2010, after running the general counsel, consumer banking and wealth management units, and he also chairs the board.
Source
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Timeline: Bank of America and Bristol-Myers Squibb side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1904Bank of America
Bank of Italy Founded
A.P. Giannini founded the Bank of Italy in San Francisco to expand access to banking for immigrants, wage earners, and small merchants.
1906Bank of America
San Francisco Earthquake Response
After the 1906 earthquake, Giannini resumed lending while much of San Francisco's banking system was disrupted. The response turned emergency access to credit into lasting customer trust and became a defining story in the bank's retail identity.
1930Bank of America
Bank of Italy Renamed Bank of America
The Bank of Italy changed its name to Bank of America on November 1, 1930. The rebrand reflected a wider consumer and business ambition beyond the original immigrant-community label.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1958Bank of America
BankAmericard Introduced
Bank of America introduced BankAmericard in 1958, a revolving-credit card that later became part of the Visa system. The product tied the bank to modern consumer credit, merchant acceptance, and payment-network economics.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1998Bank of America
NationsBank and BankAmerica Merge
The 1998 merger of Charlotte-based NationsBank and San Francisco's BankAmerica created the first coast-to-coast U.S. bank under the Bank of America name. It also shifted the modern company's headquarters center to Charlotte.
2006Bank of America
MBNA Merger Completed
The MBNA merger expanded the card business to more than 40M active accounts and nearly $140B in managed balances, according to the company's January 2006 release. That size made cards a more important part of consumer banking revenue and risk.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2008Bank of America
Countrywide Acquisition Approved
The Federal Reserve approved Bank of America's acquisition of Countrywide in June 2008. The deal added mortgage scale but later became a costly warning about buying distressed loan portfolios during a housing crisis.
2008Bank of America
Merrill Lynch Acquisition Approved
The Federal Reserve approved the acquisition of Merrill Lynch in November 2008. Although the integration was controversial, Merrill became central to the company's wealth-management and investment-banking fee base.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bank of America
Mortgage Settlements With the Justice Department and FHFA
Bank of America agreed in August 2014 to a $16.65B settlement with the Justice Department over mortgage claims tied to Countrywide and Merrill Lynch, following a March 2014 FHFA agreement with an aggregate payment of about $9.33B.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2018Bank of America
Erica Launched
Bank of America launched Erica in 2018 as an AI-enabled virtual assistant inside digital banking. The launch mattered because customer service, insights, and routine account tasks were moving from branches and call centers into mobile channels.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bank of America
CFPB and OCC Orders on Fees, Rewards and Accounts
In July 2023 the CFPB ordered Bank of America to pay more than $100M to customers for repeat non-sufficient-funds fees, withheld credit card rewards and unauthorized accounts, plus $90M in CFPB penalties, and the OCC added a $60M penalty.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bank of America
$113.1B FY2025 Revenue
The company reported $113.1B in total revenue net of interest expense and $30.5B in net income for FY2025. The result showed the combined scale of deposits, wealth management, cards, payments, global banking, and markets.
2025Bank of America
Co-Presidents Named
On September 12, 2025 Bank of America named Dean Athanasia and Jim DeMare Co-Presidents and gave Chief Financial Officer Alastair Borthwick the added title of executive vice president.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
Acquisitions
Bank of America
- Countrywide Financial2008$4B
- Merrill Lynch2008$50B
- LaSalle Bank2007$21B
- MBNA2006$35B
- FleetBoston Financial2004$47B
- BankAmerica / NationsBank merger1998$43B
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Questions about Bank of America vs Bristol-Myers Squibb
Who is the CEO of Bank of America Corporation and Bristol-Myers Squibb Company?
Bank of America Corporation is led by Brian Moynihan and Bristol-Myers Squibb Company is led by Christopher Boerner. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bank of America Corporation founded vs Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company was founded in 1887 — 17 years before Bank of America Corporation, which was founded in 1904. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Bank of America Corporation.
How many employees does Bank of America Corporation have compared to Bristol-Myers Squibb Company?
Bank of America Corporation employs approximately 213,000 people, while Bristol-Myers Squibb Company employs approximately 32,500. Bank of America Corporation has the larger workforce at 213,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bank of America Corporation and Bristol-Myers Squibb Company headquartered?
Both Bank of America Corporation and Bristol-Myers Squibb Company are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bank of America Corporation and Bristol-Myers Squibb Company?
Bank of America Corporation was founded by Amadeo Peter Giannini. Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers.
Which company has a longer operating history — Bank of America Corporation or Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Bank of America Corporation has been in operation for around 122 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bank of America vs Bristol-Myers Squibb overview